


# Blue Coast Research Center

## CURRICULUM VITAE

<b>SIGNATURE:</b>		<b>DATE:</b>	5/19/2022
<b>NAME:</b>	Anthony Serrato, MSN, BSN	<b>DATE</b>	
<b>TITLE:</b>	Sub-Investigator	<b>UPDATED:</b>	May 2022

### RESEARCH SITE NAME/ ADDRESS:

<b>Main Office:</b>  Blue Coast Research Center 2067 W. Vista Way, #225 Vista, CA 92083	Office: (760) 691-1622 Email: <a href="mailto:anthony.serrato@bluecoastcardiology.com">anthony.serrato@bluecoastcardiology.com</a>
---	---

### EDUCATION/TRAINING:

INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
United States University	Certificate	2020	MSN
CSU San Marcos, CA	Certificate	2013	BSN
Palomar College, CA	Certificate	2010	Associates
NIDA Clinical Trials Network	Certificate	2022	Good Clinical Practice
Mayo Clinic Laboratories	Certificate	2022	IATA

### POSITIONS AND EMPLOYMENT:

2022- Present	Sub-Investigator, Blue Coast Research Center, Vista, CA
2021-Present	Advanced Practice Specialist, UC San Diego Health, CA
Apr 2021- Nov 2021	NPI, UC San Diego Health, CA
2013-2021	CNNI San Diego Health, CA
2012-2013	ED Trauma Tech, UC San Diego, CA

### CLINICAL RESEARCH EXPERIENCE:

**Milestone:** Phase 3, Multi-Centre, Multi-National, Open Label, Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia

**Duke:** Phase 4, COOrdinating CaRDIology CliNics RANdomized Trial of Interventions to Improve OutcomEs (COORDINATE) – Diabetes

**Abcentra:** Phase 2, A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study with Orticumab in Subjects with Moderate-to-Severe Psoriasis and Cardiometabolic risk factors

**Bayer:** APhase 3, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction  $\geq 40\%$  (LVEF  $\geq 40\%$ ).

**Milestone:** Phase 3, An Open Label Extension Study of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia

**Merck:** Phase 3, Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Stable Heart Failure With Reduced Ejection Fraction

**Novartis:** A randomized double-blind, placebo controlled, multicenter trial, assessing the impact of Inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease